# Risk Stratification and MRD-driven Maintenance for MM After ASCT

> **NCT06697483** · NA · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06697483
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06697483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06697483, "Risk Stratification and MRD-driven Maintenance for MM After ASCT". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06697483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*